fluphenazine depot has been researched along with Schizophrenia in 199 studies
fluphenazine decanoate : The prodrug of fluphenazine, an antipsychotic drug used for the symptomatic management of psychosis in patients with schizophrenia.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy of the use of moditen-depo and haloperidol decanoate as preventive anti-recurrence+ therapy was studied and compared in 2 groups of patients suffering from attack-like schizophrenia with frequent exacerbations." | 9.06 | [Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia]. ( Kalugina, LI; Kopeĭko, GI; Kravchenko, NE; Mirzoian, MG; Ushakov, IuV, 1990) |
| "This paper reports a randomized, controlled, partially-blinded, flexible dose, parallel group, comparative study of the efficacy and tolerance of pipothiazine palmitate and fluphenazine decanoate in patients in remission from Schizophrenia over a 28 week period." | 9.06 | A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. ( Gill, RC; Leong, OK; Tay, WK; Wong, KE, 1989) |
| "To assess the effects of fluphenazine decanoate and enanthate versus oral anti-psychotics and other depot neuroleptic preparations for individuals with schizophrenia in terms of clinical, social and economic outcomes." | 8.91 | Fluphenazine decanoate (depot) and enanthate for schizophrenia. ( Adams, CE; Asher, R; David, A; Eisenbruch, M; Jayaswal, A; Maayan, N; Quraishi, SN; Rathbone, J, 2015) |
| "To compare depot fluphenazine medication to oral fluphenazine for treatment of schizophrenia." | 8.80 | Depot fluphenazine for schizophrenia. ( Adams, CE; Eisenbruch, M, 2000) |
| " This study aimed to report a case with bradycardia induced by fluphenazine decanoate administration." | 8.12 | Fluphenazine decanoate-induced bradycardia: A case report. ( Azizi, M; Elyasi, F; Kamali, M; Zarghami, M, 2022) |
| " Results suggested an absorption half-life of 4 weeks, although, in three cases steady state was only achieved after 11 monthly injections." | 6.67 | Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia. ( McCreadie, RG; Whitehead, A; Wiles, DH, 1990) |
| " The dosage equivalency of haloperidol decanoate (1." | 6.66 | A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. ( Annable, L; Campbell, W; Chouinard, G, 1989) |
| "Fluphenazine was significantly effective in treating symptoms such as emotional withdrawal, blunted affect, suspiciousness, thought disturbances, but not hallucinations." | 5.28 | Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia. ( Altamura, AC; Girardi, T; Mauri, MC; Panetta, B, 1990) |
| " Based on the study of plasma levels achieved with FPZ-D injection and oral FPZ-H (fluphenazine HC1) in 6 patients, the dosage requirement of FPZ-D appeared to be difficult to predict from the oral dosage of FPZ-H in the same patient." | 5.27 | Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia. ( Casper, RC; Chang, SS; Davis, JM; Dysken, MW; Janicak, PG; Javaid, JI, 1985) |
| "Long-acting injectable risperidone was assessed in schizophrenia patients who were symptomatically stable on conventional depot antipsychotics and who were then switched to long-acting risperidone." | 5.11 | Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. ( Eerdekens, E; Eerdekens, M; Jacko, M; Turner, M, 2004) |
| " With this in mind, we evaluated the usefulness of monitoring fluphenazine plasma levels for patients with schizophrenia who were receiving maintenance treatment with fluphenazine decanoate." | 5.10 | Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate. ( Aravagiri, M; Lebell, M; Marder, SR; Mintz, J; Wirshing, DA; Wirshing, WC, 2002) |
| "Fifty outpatients with schizophrenia or schizoaffective disorder were randomly assigned to receive 25 mg of fluphenazine decanoate intramuscularly either every 2 weeks or every 6 weeks for 54 weeks in a double-blind design." | 5.09 | Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. ( Breier, AF; Buchanan, RW; Carpenter, WT; Kirkpatrick, B; Lann, HD; Summerfelt, AT, 1999) |
| "Forty-one patients with DSM-III schizophrenia or schizoaffective disorder were assigned to either adjunctive lithium or placebo after at least 6 months of fluphenazine decanoate treatment to stabilize symptoms had failed." | 5.09 | Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. ( Glick, ID; Jacobs, M; Ninan, PT; Odbert, CL; Robinson, D; Schulz, SC; Thompson, PA; Weiden, PJ; Yadalam, K, 1999) |
| "Fifty-three volunteer patients with recent-onset schizophrenia who had been clinically stabilized on a maintenance regimen of fluphenazine decanoate for a mean of 16." | 5.09 | Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. ( Aravagiri, M; Bartzokis, G; Fogelson, DL; Gitlin, M; Mintz, J; Nuechterlein, K; Subotnik, KL; Ventura, J, 2001) |
| "This study examined substance use among a group of 37 schizophrenia patients participating in a year-long fluphenazine decanoate (FD; Prolixin) dosage reduction study (Inderbitzin et al." | 5.08 | Substance use: a powerful predictor of relapse in schizophrenia. ( Inderbitzin, LB; Kasckow, JW; Scheller-Gilkey, G; Swofford, CD, 1996) |
| "Eighty male outpatients with schizophrenia were stabilized with a low dose of fluphenazine decanoate (5 to 10 mg every 14 days), which was supplemented with oral fluphenazine (5 mg twice daily) or a placebo when they first met criteria for a prodromal period." | 5.08 | Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. ( Eckman, TA; Johnston, K; Lebell, M; Liberman, RP; Marder, SR; McKenzie, J; Mintz, J; Wirshing, WC; Zimmerman, K, 1996) |
| "This study evaluated the feasibility and impact of gradually reducing relatively high doses of fluphenazine decanoate by one-half for chronically impaired, poor inner-city patients with schizophrenia." | 5.07 | A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. ( Egan, GJ; Gloersen, BA; Inderbitzin, LB; Lewine, RR; Scheller-Gilkey, G; Swofford, CD; Vidanagama, BP; Waternaux, C, 1994) |
| "This paper reports a randomized, controlled, partially-blinded, flexible dose, parallel group, comparative study of the efficacy and tolerance of pipothiazine palmitate and fluphenazine decanoate in patients in remission from Schizophrenia over a 28 week period." | 5.06 | A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. ( Gill, RC; Leong, OK; Tay, WK; Wong, KE, 1989) |
| " All patients had been diagnosed as having schizophrenia or schizoaffective disorder, all were receiving stable doses of fluphenazine decanoate, and all had received benztropine mesylate in an attempt to rule out neuroleptic-induced akinesia." | 5.06 | Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial. ( Cooper, TB; Fagerstrom, R; Morgan, V; Rifkin, A; Siris, SG, 1987) |
| "The efficacy of the use of moditen-depo and haloperidol decanoate as preventive anti-recurrence+ therapy was studied and compared in 2 groups of patients suffering from attack-like schizophrenia with frequent exacerbations." | 5.06 | [Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia]. ( Kalugina, LI; Kopeĭko, GI; Kravchenko, NE; Mirzoian, MG; Ushakov, IuV, 1990) |
| "In an attempt to begin to establish minimum effective dosage requirements for the maintenance treatment of schizophrenia, we undertook a double-blind comparison of low-dose fluphenazine decanoate (1." | 5.05 | Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. ( Kane, JM; Ramos-Lorenzi, J; Reardon, G; Rifkin, A; Sarantakos, S; Schiebel, D; Woerner, M, 1983) |
| "To assess the effects of fluphenazine decanoate and enanthate versus oral anti-psychotics and other depot neuroleptic preparations for individuals with schizophrenia in terms of clinical, social and economic outcomes." | 4.91 | Fluphenazine decanoate (depot) and enanthate for schizophrenia. ( Adams, CE; Asher, R; David, A; Eisenbruch, M; Jayaswal, A; Maayan, N; Quraishi, SN; Rathbone, J, 2015) |
| "To compare depot fluphenazine medication to oral fluphenazine for treatment of schizophrenia." | 4.80 | Depot fluphenazine for schizophrenia. ( Adams, CE; Eisenbruch, M, 2000) |
| " This study aimed to report a case with bradycardia induced by fluphenazine decanoate administration." | 4.12 | Fluphenazine decanoate-induced bradycardia: A case report. ( Azizi, M; Elyasi, F; Kamali, M; Zarghami, M, 2022) |
| "We describe the case of a 39-year-old patient with schizophrenia who developed worsening of glucose metabolism during treatment with two different atypical antipsychotics, clozapine and quetiapine." | 3.73 | Importance of oral glucose tolerance test in patient with schizophrenia. ( Aukst-Margetić, B; Badanjak, A; Margetić, B, 2005) |
| "We examined the effect of age on psychopharmacological management in a naturalistic study of a group of 165 patients with a clinical diagnosis of schizophrenia or a related psychotic disorder (age range = 21-84 years; subjects > or = 1;45 years n = 86) treated with either haloperidol decanoate or fluphenazine decanoate." | 3.71 | The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders. ( Chengappa, KN; Jeste, DV; Mamo, DC; Reddy, RR; Sweet, RA, 2002) |
| "Longitudinal assessment and management of the patient resulted in a diagnosis of schizophrenia and treatment with fluphenazine decanoate." | 3.69 | Intervention and social breakdown in the elderly. ( Little, JD, 1996) |
| "Plasma prolactin and fluphenazine concentrations were measured in a group of 17 patients (9 males, 8 females) with schizophrenia who were receiving chronic treatment with fluphenazine decanoate." | 3.67 | Plasma prolactin and fluphenazine concentrations in patients receiving fluphenazine decanoate: stability over injection intervals. ( Burrows, GD; Kimber, NM; Marriott, PF; Norman, TR, 1987) |
| "A patient with chronic schizophrenia treated with fluphenazine developed neuroleptic malignant syndrome, characterized by fever, obtundation, rigidity, and tremulousness." | 3.66 | Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine. ( Adler, S; Coyle, J; Granato, JE; Karim, AH; Krumholz, A; Ringel, A; Stern, BJ, 1983) |
| "Since schizophrenia is a common condition and treatment is usually long-term, this has important financial implications." | 2.69 | Generic substitution--comparing the clinical efficacy of a generic substitute for fluphenazine decanoate with the original product. ( Joubert, G; Stevens, M; van der Merwe, H; Verster, GC, 1998) |
| " Dosage data from the first 208 successfully-stabilized TSS subjects were examined." | 2.67 | Stabilization and depot neuroleptic dosages. ( Lee, JH; Schooler, NR; Schulz, SC; Severe, JB; Weiden, P, 1993) |
| " Results suggested an absorption half-life of 4 weeks, although, in three cases steady state was only achieved after 11 monthly injections." | 2.67 | Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia. ( McCreadie, RG; Whitehead, A; Wiles, DH, 1990) |
| " Sixteen stable outpatients participated in a two-way crossover design study of the bioavailability of a new formulation of FPZ Dec, i." | 2.67 | The determination of the steady-state pharmacokinetic profile of fluphenazine decanoate by gas chromatography/mass spectrometry detection. ( Brown, WA; Friedhoff, LT; Glazer, WM; Marder, SR, 1992) |
| " The dosage equivalency of haloperidol decanoate (1." | 2.66 | A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. ( Annable, L; Campbell, W; Chouinard, G, 1989) |
| " When plasma levels from both dosage groups were combined, FLU at 12 weeks correlated significantly with factor scores for akinesia (r = 0." | 2.66 | Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate. ( Hawes, EM; Hubbard, JW; Marder, SR; May, PR; McKay, G; Midha, KK; Mintz, J; Van Putten, T, 1986) |
| " There was no significant difference in survival when the clinician was permitted to make a dosage adjustment up to 10 mg in the low-dose group and 50 mg in the higher-dose group when the patient demonstrated evidence of a symptomatic exacerbation." | 2.66 | Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome. ( Lebell, M; Marder, SR; May, PR; McKenzie, J; Mintz, J; Van Putten, T, 1987) |
| " The evidence available from prospective controlled trials suggests that substantial dosage reduction is feasible for a subgroup of outpatient schizophrenics and that the incidence of abnormal involuntary movements might be reduced by such a strategy." | 2.65 | Low dose medication strategies in the maintenance treatment of schizophrenia. ( Kane, JM, 1983) |
| " Maximum concentrations appeared at 1 week after administration of cis(Z)-clopenthixol decanoate, whereas the highest concentrations after fluphenazine decanoate were seen at the end of the 3-week dosage interval." | 2.65 | Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters. ( Ba, B; Berda, C; D'Agostino, N; Dufour, H; Durand, A; Hou, N; Jørgensen, A; Viala, A, 1984) |
| " In addition, the clinician should consider the dosage schedule of each medication and balance this against the probability of extrapyramidal side effects and noncompliance." | 2.38 | Dose response of prophylactic antipsychotics. ( Brauzer, B; Casey, DE; Davis, JM; Gierl, B; Hassan, M; Kane, JM; Marder, SR; Schooler, N, 1993) |
| "9% of the total antipsychotic dosage on average." | 1.39 | Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review. ( Den, R; Mimura, M; Sakurai, H; Suzuki, T; Tsutsumi, C; Uchida, H; Uchida, T, 2013) |
| "Schizophrenia is thought to be the psychiatric diagnosis the most frequently associated with TD." | 1.39 | [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics]. ( Bellaaj, R; Bouguerra, C; Gallali, S; Mehdi, F; Oumaya, A; Sejil, I, 2013) |
| "Schizophrenia Care and Assessment Program, a large, prospective study of treatment for schizophrenia conducted July 1997 through September 2003." | 1.34 | Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. ( Ascher-Svanum, H; Faries, D; Marder, SR; Montgomery, W; Shi, L; Zhu, B, 2007) |
| " The average dosage was 251." | 1.30 | Age at onset of schizophrenia and neuroleptic dosage. ( Dernovsek, MZ; Tavcar, R, 1999) |
| "Treatment of schizophrenia is often complicated by substance abuse." | 1.30 | Alcohol dependence and hospitalization in schizophrenia. ( Arana, GW; Gerding, LB; Labbate, LA; Measom, MO; Santos, AB, 1999) |
| "Fluphenazine was significantly effective in treating symptoms such as emotional withdrawal, blunted affect, suspiciousness, thought disturbances, but not hallucinations." | 1.28 | Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia. ( Altamura, AC; Girardi, T; Mauri, MC; Panetta, B, 1990) |
| "The neuroleptic malignant syndrome is an exceedingly rare but potentially fatal condition characterized by parkinsonian type rigidity, rise of temperature and altered consciousness." | 1.28 | An unusual presentation of neuroleptic malignant syndrome. ( Basu, J, 1991) |
| "Seventeen outpatients were treated with depot neuroleptics, zuclopenthixol decanoate in Viscoleo or fluphenazine decanoate in sesame oil, with dosage intervals of 3 weeks." | 1.27 | Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. ( Ba, B; Durand, A; Gouezo, F; Hou, N; Jørgensen, A; Viala, A, 1988) |
| "Haloperidol was given to 8 patients for 10 days (group A: 0." | 1.27 | Effects of neuroleptic treatments on peripheral opioid secretion. ( Bellodi, L; Brambilla, F; Brancato, V; Facchinetti, F; Genazzani, AR; Petraglia, F; Smeraldi, E, 1987) |
| " There were statistically significant tendencies for mean plasma fluphenazine levels to rise and mean plasma sulfoxide levels to fall over the 6-month period of study among patients on the high dose, consistent with our previously reported observation that it takes 3-6 months to establish a steady state of fluphenazine with this dosage regimen." | 1.27 | The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate. ( Hawes, EM; Hubbard, JW; Marder, SR; May, PR; McKay, G; Midha, KK; Van Putten, T, 1987) |
| " Based on the study of plasma levels achieved with FPZ-D injection and oral FPZ-H (fluphenazine HC1) in 6 patients, the dosage requirement of FPZ-D appeared to be difficult to predict from the oral dosage of FPZ-H in the same patient." | 1.27 | Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia. ( Casper, RC; Chang, SS; Davis, JM; Dysken, MW; Janicak, PG; Javaid, JI, 1985) |
| " To gather relevant data on pharmacokinetic characteristics of depot fluphenazines, the authors measured plasma levels of neuroleptic activity in 76 clinic patients on stable dosage regimens of fluphenazine decanoate or fluphenazine enanthate." | 1.27 | Plasma levels of neuroleptic in patients receiving depot fluphenazine. ( Chouinard, G; Cohen, BM; Jones, B; Sommer, BR; Waternaux, C, 1985) |
| "In 14 schizophrenic patients, prolactin levels are studied in relation to dosage of depot fluphenazine and gender of patient." | 1.27 | Depot fluphenazine and plasma prolactin. ( Gift, T; Plum, K; Price, M, 1985) |
| "281 newly admitted female schizophrenic patients were treated with high dosage fluphenazine decanoate intramuscularly, starting with 250 mg per injection together with antiparkinsonian and antidepressant drugs." | 1.26 | Follow-up study of 281 schizophrenic patients treated with high dosage fluphenazine decanoate. ( Nagy, C; Steiner, S, 1981) |
| "This high rate of relapse is viewed as indicating the need for continued medication in most chronic schizophrenic patients." | 1.26 | Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. ( Aderounmu, AF; Odejide, OA, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 124 (62.31) | 18.7374 |
| 1990's | 52 (26.13) | 18.2507 |
| 2000's | 15 (7.54) | 29.6817 |
| 2010's | 7 (3.52) | 24.3611 |
| 2020's | 1 (0.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kamali, M | 1 |
| Zarghami, M | 1 |
| Azizi, M | 1 |
| Elyasi, F | 1 |
| Kirk Morton, N | 1 |
| Zubek, D | 1 |
| Stanković, Z | 2 |
| Ille, T | 2 |
| Uchida, T | 1 |
| Suzuki, T | 1 |
| Sakurai, H | 1 |
| Tsutsumi, C | 1 |
| Den, R | 1 |
| Mimura, M | 1 |
| Uchida, H | 1 |
| Maayan, N | 1 |
| Quraishi, SN | 1 |
| David, A | 1 |
| Jayaswal, A | 1 |
| Eisenbruch, M | 2 |
| Rathbone, J | 1 |
| Asher, R | 1 |
| Adams, CE | 2 |
| Rajarethinam, R | 1 |
| Dziuba, J | 1 |
| Manji, S | 1 |
| Pizzuti, A | 1 |
| Lachover, L | 1 |
| Keshavan, M | 1 |
| Citrome, L | 1 |
| Jaffe, A | 1 |
| Levine, J | 1 |
| John, SM | 1 |
| Venkatesan, S | 1 |
| Tharyan, A | 1 |
| Bhattacharji, S | 1 |
| Sejil, I | 1 |
| Oumaya, A | 1 |
| Bouguerra, C | 1 |
| Mehdi, F | 1 |
| Bellaaj, R | 1 |
| Gallali, S | 1 |
| Mamo, DC | 1 |
| Sweet, RA | 1 |
| Chengappa, KN | 1 |
| Reddy, RR | 1 |
| Jeste, DV | 1 |
| Conley, RR | 2 |
| Kelly, DL | 2 |
| Love, RC | 2 |
| McMahon, RP | 1 |
| Turner, M | 1 |
| Eerdekens, E | 1 |
| Jacko, M | 1 |
| Eerdekens, M | 1 |
| Margetić, B | 2 |
| Aukst-Margetić, B | 1 |
| Badanjak, A | 1 |
| McEvoy, JP | 2 |
| Baptista, T | 1 |
| Martinez, M | 1 |
| Lacruz, A | 1 |
| Arellano, A | 1 |
| Mendoza, S | 1 |
| Beaulieu, S | 1 |
| Hernández, L | 1 |
| Contreras, Q | 1 |
| Galeazzi, T | 1 |
| Vargas, D | 1 |
| Glazer, WM | 3 |
| Shi, L | 1 |
| Ascher-Svanum, H | 1 |
| Zhu, B | 1 |
| Faries, D | 1 |
| Montgomery, W | 1 |
| Marder, SR | 16 |
| Aukst Margetić, B | 1 |
| Small, JG | 1 |
| Kellams, J | 1 |
| Britvić, D | 1 |
| Vuković, O | 1 |
| Waddington, JL | 1 |
| Gamble, SJ | 1 |
| Chouinard, G | 4 |
| Annable, L | 3 |
| Ross-Chouinard, A | 1 |
| Braddock, LE | 1 |
| Blake, IM | 1 |
| Balon, R | 1 |
| Kabesh, Ia | 1 |
| Papezhova, G | 1 |
| Mandel, MR | 1 |
| Severe, JB | 3 |
| Schooler, NR | 3 |
| Gelenberg, AJ | 1 |
| Mieske, M | 1 |
| van der Kolk, BA | 1 |
| Goldberg, HL | 1 |
| Walker, CA | 1 |
| Johnson, DA | 1 |
| Pasterski, G | 1 |
| Ludlow, JM | 1 |
| Street, K | 1 |
| Taylor, RD | 1 |
| Hogan, TP | 1 |
| Awad, AG | 1 |
| Lapierre, YD | 2 |
| von Frenckell, R | 1 |
| Müller, P | 1 |
| Kane, JM | 7 |
| Oyewumi, LK | 1 |
| Gray, R | 1 |
| Batth, S | 1 |
| Gelfand, R | 1 |
| Dencker, SJ | 1 |
| Hogarty, GE | 3 |
| Leff, J | 1 |
| Kuipers, L | 1 |
| Berkowitz, R | 1 |
| Eberlein-Fries, R | 1 |
| Sturgeon, D | 1 |
| Ostow, M | 1 |
| Viala, A | 2 |
| Hou, N | 2 |
| Ba, B | 2 |
| Durand, A | 2 |
| Dufour, H | 1 |
| D'Agostino, N | 1 |
| Berda, C | 1 |
| Jørgensen, A | 2 |
| Asarnow, RF | 2 |
| Van Putten, T | 9 |
| Rifkin, A | 5 |
| Quitkin, F | 1 |
| Nayak, D | 2 |
| Ramos-Lorenzi, J | 2 |
| Woerner, M | 2 |
| Reardon, G | 2 |
| Sarantakos, S | 1 |
| Schiebel, D | 1 |
| Wistedt, B | 3 |
| Ranta, J | 1 |
| McCreadie, RG | 3 |
| McKane, JP | 2 |
| Mackie, M | 2 |
| Watt, DC | 1 |
| Katz, K | 1 |
| Shepherd, M | 1 |
| Barnes, TR | 4 |
| Milavic, G | 1 |
| Curson, DA | 4 |
| Platt, SD | 4 |
| Campbell, W | 2 |
| Boisvert, D | 1 |
| Bradwejn, J | 1 |
| Mintz, J | 10 |
| McKenzie, J | 3 |
| Lebell, M | 4 |
| Faltico, G | 1 |
| May, PR | 4 |
| Michel, G | 1 |
| Vásquez, R | 1 |
| Basso, L | 1 |
| Waldmann, KD | 1 |
| Neumann, J | 1 |
| Marriott, P | 1 |
| Pansa, M | 1 |
| Hiep, A | 1 |
| Granato, JE | 1 |
| Stern, BJ | 1 |
| Ringel, A | 1 |
| Karim, AH | 1 |
| Krumholz, A | 1 |
| Coyle, J | 2 |
| Adler, S | 1 |
| Palmstierna, T | 1 |
| Ngui, PW | 1 |
| Mattes, JA | 1 |
| Perényi, A | 1 |
| Arató, M | 1 |
| Shear, MK | 1 |
| Frances, A | 2 |
| Weiden, P | 2 |
| Gaby, N | 1 |
| Lefkowitz, D | 1 |
| Israel, JR | 1 |
| Siris, SG | 12 |
| Cooper, TB | 5 |
| Rifkin, AE | 1 |
| Brenner, R | 1 |
| Lieberman, JA | 2 |
| Polácek, J | 1 |
| Odejide, OA | 1 |
| Aderounmu, AF | 1 |
| McCreadie, R | 1 |
| Morrison, D | 1 |
| Kidd, J | 1 |
| Harris, PQ | 1 |
| Friedman, MJ | 1 |
| Cohen, BM | 2 |
| Russell, N | 1 |
| Landmark, J | 2 |
| Merskey, H | 2 |
| Turpin, T | 1 |
| Steiner, S | 2 |
| Filotto, JF | 1 |
| Nagy, C | 1 |
| Tan, CT | 1 |
| Ong, TC | 1 |
| Chee, KT | 1 |
| Zhang, YF | 1 |
| Tompson, MC | 1 |
| Goldstein, MJ | 2 |
| Lebell, MB | 1 |
| Mintz, LI | 1 |
| Goff, DC | 1 |
| Midha, KK | 5 |
| Sarid-Segal, O | 1 |
| Hubbard, JW | 4 |
| Amico, E | 1 |
| Miller, RS | 1 |
| Peterson, GM | 1 |
| McLean, S | 1 |
| Westhead, TT | 1 |
| Gillies, P | 1 |
| Ulrich, RF | 1 |
| DiBarry, AL | 1 |
| Bartone, P | 1 |
| Cooley, S | 1 |
| Hammill, K | 1 |
| Carter, M | 1 |
| Munetz, MR | 1 |
| Perel, J | 1 |
| Gall, JA | 1 |
| Drummer, OH | 1 |
| Landgren, AJ | 1 |
| Bermanzohn, PC | 1 |
| Mason, SE | 2 |
| Shuwall, MA | 1 |
| Inderbitzin, LB | 3 |
| Lewine, RR | 2 |
| Scheller-Gilkey, G | 2 |
| Swofford, CD | 2 |
| Egan, GJ | 1 |
| Gloersen, BA | 2 |
| Vidanagama, BP | 2 |
| Waternaux, C | 2 |
| Soni, SD | 4 |
| Gaskell, K | 1 |
| Reed, P | 1 |
| Cernovsky, ZZ | 1 |
| Davis, JM | 2 |
| Brauzer, B | 1 |
| Gierl, B | 1 |
| Schooler, N | 1 |
| Casey, DE | 1 |
| Hassan, M | 1 |
| Lee, JH | 1 |
| Schulz, SC | 2 |
| Stone, AM | 1 |
| Greenstein, RA | 1 |
| Gamble, G | 2 |
| McLellan, AT | 1 |
| de Nesnera, AP | 1 |
| Heresco-Levy, U | 3 |
| Greenberg, D | 3 |
| Lerer, B | 3 |
| Dasberg, H | 2 |
| Brown, WA | 4 |
| Robinson, D | 2 |
| Woerner, MG | 2 |
| Pollack, S | 1 |
| Lerner, G | 1 |
| Hawton, K | 1 |
| Ware, C | 1 |
| Mistry, H | 1 |
| Hewitt, J | 1 |
| Kingsbury, S | 1 |
| Roberts, D | 1 |
| Weitzel, H | 1 |
| Kasckow, JW | 1 |
| Little, JD | 1 |
| Spivak, B | 1 |
| Gonen, N | 1 |
| Mester, R | 1 |
| Averbuch, E | 1 |
| Adlersberg, S | 1 |
| Weizman, A | 1 |
| Wirshing, WC | 3 |
| Johnston, K | 1 |
| Eckman, TA | 1 |
| Zimmerman, K | 1 |
| Liberman, RP | 1 |
| Dhopesh, V | 1 |
| Macfadden, A | 1 |
| Maany, I | 1 |
| Keith, SJ | 1 |
| Matthews, SM | 1 |
| Bellack, AS | 1 |
| Glick, ID | 2 |
| Hargreaves, WA | 1 |
| Ninan, PT | 2 |
| Jacobs, M | 2 |
| Mance, R | 1 |
| Simpson, GM | 2 |
| Javitt, DC | 1 |
| Verster, GC | 1 |
| Joubert, G | 1 |
| Stevens, M | 1 |
| van der Merwe, H | 1 |
| Yee, CM | 2 |
| Nuechterlein, KH | 4 |
| Morris, SE | 1 |
| White, PM | 1 |
| Moore, DB | 1 |
| Sherr, JD | 1 |
| Carpenter, WT | 1 |
| Buchanan, RW | 1 |
| Kirkpatrick, B | 1 |
| Lann, HD | 1 |
| Breier, AF | 1 |
| Summerfelt, AT | 1 |
| Thompson, PA | 1 |
| Weiden, PJ | 1 |
| Yadalam, K | 1 |
| Odbert, CL | 1 |
| Gerding, LB | 1 |
| Labbate, LA | 1 |
| Measom, MO | 1 |
| Santos, AB | 1 |
| Arana, GW | 1 |
| Dernovsek, MZ | 1 |
| Tavcar, R | 1 |
| Linn, GS | 1 |
| Lifshitz, K | 1 |
| O'Keeffe, RT | 1 |
| Lee, K | 1 |
| Camp-Lifshitz, J | 1 |
| Gitlin, M | 4 |
| Nuechterlein, K | 2 |
| Subotnik, KL | 1 |
| Ventura, J | 3 |
| Fogelson, DL | 1 |
| Bartzokis, G | 1 |
| Aravagiri, M | 4 |
| Wirshing, DA | 1 |
| Hoencamp, E | 1 |
| Haffmans, PJ | 1 |
| Jansen, GS | 1 |
| Sampath, G | 1 |
| Shah, A | 1 |
| Krska, J | 1 |
| Bergen, J | 1 |
| Kitchin, R | 1 |
| Berry, G | 1 |
| Sachdev, P | 2 |
| Tang, WM | 1 |
| Dawson, ME | 2 |
| Snyder, KS | 2 |
| Hardesty, JP | 1 |
| Friedhoff, LT | 1 |
| McClelland, HA | 1 |
| Metcalfe, AV | 1 |
| Kerr, TA | 1 |
| Dutta, D | 1 |
| Watson, P | 1 |
| Chabert, N | 1 |
| Samuel, G | 1 |
| Hawes, EM | 3 |
| McKay, G | 3 |
| Brownlee, M | 1 |
| Ushakov, IuV | 2 |
| Kravchenko, NE | 2 |
| Kopeĭko, GI | 1 |
| Kalugina, LI | 1 |
| Mirzoian, MG | 1 |
| Basu, J | 1 |
| Altamura, AC | 3 |
| Mauri, MC | 2 |
| Girardi, T | 1 |
| Panetta, B | 1 |
| Durst, P | 1 |
| Schuff, N | 1 |
| Crocq, MA | 1 |
| Mokrani, MC | 1 |
| Macher, JP | 1 |
| Commander, M | 1 |
| Dean, C | 1 |
| Geller, J | 1 |
| Gingerich, S | 1 |
| Wiles, DH | 3 |
| Whitehead, A | 1 |
| Clovis, WL | 1 |
| Rosen, PB | 1 |
| McDonald, SC | 1 |
| Jann, MW | 2 |
| Fidone, GS | 1 |
| Hernandez, JM | 1 |
| Amrung, S | 1 |
| Davis, CM | 2 |
| Faraone, SV | 1 |
| Green, AI | 1 |
| Brown, W | 1 |
| Yin, P | 1 |
| Tsuang, MT | 1 |
| Wittman, L | 1 |
| Leong, OK | 1 |
| Wong, KE | 1 |
| Tay, WK | 1 |
| Gill, RC | 1 |
| Neehall, J | 1 |
| Aronson, A | 3 |
| Sellew, AP | 2 |
| Kong, DS | 2 |
| Yeo, SH | 2 |
| Hirsch, SR | 4 |
| Jolley, AG | 1 |
| Cooper, SJ | 1 |
| Doherty, MM | 1 |
| King, DJ | 1 |
| Adan, F | 4 |
| Filip, V | 2 |
| Faltus, F | 1 |
| Hanáková, S | 1 |
| Janecková, E | 1 |
| Raboch, J | 1 |
| Dobiásová, A | 1 |
| Karen, P | 1 |
| Posmurová, M | 1 |
| Borenstein, M | 2 |
| Smulevich, AB | 1 |
| Vorob'ev, VIu | 1 |
| Dubnitskaia, EB | 1 |
| Maksimov, VI | 1 |
| Novikov, VN | 1 |
| Teicher, MH | 1 |
| Baldessarini, RJ | 1 |
| Kolakowska, T | 2 |
| Williams, AO | 2 |
| Ardern, M | 2 |
| Lazarus, A | 1 |
| Reveley, MA | 1 |
| Niss, AI | 1 |
| Shibakova, TL | 1 |
| Carotti, P | 1 |
| Merli, R | 1 |
| David, I | 1 |
| Hellerová, P | 1 |
| Fombonne, E | 1 |
| Peron-Magnan, P | 1 |
| Fuhrer, R | 1 |
| Simon, P | 1 |
| Dinan, TG | 1 |
| Bartkó, G | 1 |
| Herczeg, I | 1 |
| Zádor, G | 1 |
| Gouezo, F | 1 |
| Brambilla, F | 1 |
| Facchinetti, F | 1 |
| Petraglia, F | 1 |
| Smeraldi, E | 1 |
| Bellodi, L | 1 |
| Brancato, V | 1 |
| Genazzani, AR | 1 |
| Boza, RA | 1 |
| Milanes, F | 1 |
| Starkey, T | 1 |
| Slater, V | 1 |
| Dominguez, F | 1 |
| Zimmerman, KE | 1 |
| Cohen, M | 2 |
| Mandeli, J | 3 |
| Casey, E | 3 |
| Guercetti, G | 1 |
| Cazzullo, CL | 1 |
| Klein, A | 1 |
| Ehle, G | 1 |
| Kitamura, T | 1 |
| McGovern, DA | 1 |
| Imlah, NW | 1 |
| Wiles, D | 2 |
| Schiff, AA | 2 |
| Strahan, A | 2 |
| Bamrah, JS | 1 |
| Frechen, K | 1 |
| Mandell, J | 1 |
| Robinson, AD | 1 |
| Stirling, GS | 1 |
| Lee, A | 1 |
| Gitlin, MJ | 1 |
| Fogelson, D | 2 |
| Kreisman, D | 1 |
| Blumenthal, R | 1 |
| Kane, J | 1 |
| Yadalam, KG | 1 |
| Turbott, J | 1 |
| Villiger, J | 1 |
| Hunter, L | 1 |
| Irwin, M | 1 |
| Fuentenebro, F | 1 |
| Yuwiler, A | 1 |
| Ereshefsky, L | 1 |
| Saklad, SR | 1 |
| Cookson, JC | 1 |
| Kennedy, NM | 1 |
| Gribbon, D | 1 |
| Morgan, V | 1 |
| Fagerstrom, R | 1 |
| Anderson, CM | 1 |
| Reiss, DJ | 1 |
| Fasano-Dube, B | 1 |
| Cassino, T | 1 |
| Spellman, N | 1 |
| Heiman, J | 1 |
| Shupe, J | 1 |
| Sklebar, HT | 1 |
| Norman, TR | 1 |
| Marriott, PF | 1 |
| Kimber, NM | 1 |
| Burrows, GD | 1 |
| Jayaram, G | 1 |
| Tune, L | 1 |
| Blum, A | 1 |
| Rappe, S | 1 |
| Lesch, OM | 1 |
| Dietzel-Rogan, M | 1 |
| Musalek, M | 1 |
| Rajna, P | 1 |
| Rustembegovich, A | 1 |
| Schjerve, M | 1 |
| Walter, H | 1 |
| Bamber, RW | 3 |
| Duffy, JC | 3 |
| Curry, SH | 1 |
| Montgomery, S | 1 |
| Chang, SS | 1 |
| Javaid, JI | 1 |
| Dysken, MW | 1 |
| Casper, RC | 1 |
| Janicak, PG | 1 |
| Hinterhuber, H | 1 |
| Neumann, R | 1 |
| Reardon, GT | 1 |
| Doddi, SR | 1 |
| Hall, KS | 1 |
| Silver, MA | 1 |
| Kissling, W | 1 |
| Möller, HJ | 1 |
| Walter, K | 1 |
| Wittmann, B | 1 |
| Krueger, R | 1 |
| Trenk, D | 1 |
| Rapisarda, V | 1 |
| Bonomo, V | 1 |
| Parisi, R | 1 |
| Sommer, BR | 1 |
| Jones, B | 1 |
| Gift, T | 1 |
| Plum, K | 1 |
| Price, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Alterations in mRNA and Protein Expression in Human Peripheral Mononuclear Blood Cells (PMC) of Schizophrenia Patients Treated With Fluvoxamine Augmentation of Antipsychotics: Relationship to Clinical Symptoms and Cognitive Function[NCT00645580] | 15 participants (Anticipated) | Interventional | 2008-04-30 | Active, not recruiting | |||
| Pharmacological Approach to Improve the Outcome of Social Cognition Training[NCT01517360] | Phase 1 | 27 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics[NCT03376763] | Phase 4 | 201 participants (Actual) | Interventional | 2017-11-21 | Completed | ||
| A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis[NCT00337350] | Phase 4 | 20 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Acute insulin response to glucose (AIRG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. AIRG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. AIRG measures the acute(0-10 min) beta cell response to a glucose load calculated by the areas under the curve higher than basal insulin values. The AIRG was assessed as the incremental area under the curve (calculated by the trapezoid rule) from 0 to 10 min of the FSIVGTT. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | Units/mL per 10 minutes (Mean) |
|---|---|
| Rosiglitazone | -151 |
| Placebo | 19 |
Insulin Sensitivity (IS) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in IS between Baseline and week 8. SI was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SI represents the increase in net fractional glucose clearance rate per unit change in serum insulin concentration after the intravenous glucose load (microUnits/mL). (NCT00337350)
Timeframe: baseline, week 8
| Intervention | microUnits/mL (Mean) |
|---|---|
| Rosiglitazone | 3.2 |
| Placebo | 0.4 |
Glucose utilization (SG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. SG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SG represents the net fractional glucose clearance rate because of the increase in glucose independent of any increase in circulating insulin concentrations above baseline. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Rosiglitazone | .002 |
| Placebo | -0.01 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
8 reviews available for fluphenazine depot and Schizophrenia
| Article | Year |
|---|---|
Fluphenazine decanoate (depot) and enanthate for schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Delayed-Action Preparations; Fluphenazine; Humans; Injec | 2015 |
Risks versus benefits of different types of long-acting injectable antipsychotics.
Topics: Administration, Oral; Antipsychotic Agents; Fluphenazine; Haloperidol; Health Care Costs; Humans; In | 2006 |
Depot fluphenazine: risk/benefit ratio.
Topics: Administration, Oral; Basal Ganglia Diseases; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Fe | 1984 |
The use of depot neuroleptics: clinical experience in the United States.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Depressive Disorder; Drug Administration Sche | 1984 |
Dose response of prophylactic antipsychotics.
Topics: Administration, Oral; Aftercare; Antipsychotic Agents; Combined Modality Therapy; Delayed-Action Pre | 1993 |
Depot fluphenazine for schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Fluphenazine; Humans; Schizophrenia | 2000 |
Neuroleptic plasma levels.
Topics: Antipsychotic Agents; Biological Availability; Chlorpromazine; Fluphenazine; Haloperidol; Humans; Pe | 1991 |
Low-dose treatment strategies.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, | 1986 |
73 trials available for fluphenazine depot and Schizophrenia
| Article | Year |
|---|---|
Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.
Topics: Adult; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Dose-Response Relationship, | 2004 |
Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.
Topics: Adult; Antipsychotic Agents; Appetite; Benzodiazepines; Blood Glucose; Chronic Disease; Delayed-Acti | 2007 |
Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Doub | 1982 |
Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics.
Topics: Adolescent; Adult; Antipsychotic Agents; Clinical Trials as Topic; Depressive Disorder; Double-Blind | 1982 |
A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
Topics: Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Clopenthixol; Delayed-Action Prepar | 1983 |
Low dose medication strategies in the maintenance treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Re | 1983 |
Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.
Topics: Antipsychotic Agents; Attitude to Health; Behavior Therapy; Clinical Trials as Topic; Family; Family | 1984 |
Psychosocial relevance and benefit of neuroleptic maintenance: experience in the United Kingdom.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Attitude to Health; Clinical Trials as Topic; Delayed | 1984 |
Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters.
Topics: Adult; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Fluphenazine; Humans; Inject | 1984 |
Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia.
Topics: Adult; Aftercare; Double-Blind Method; Female; Fluphenazine; Humans; Male; Psychiatric Status Rating | 1982 |
Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates.
Topics: Adult; Ambulatory Care; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; | 1983 |
Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Depression; Double-Blind Method; Flupenthixo | 1983 |
Weekly pimozide versus fluphenazine decanoate in schizophrenic out-and day-patients.
Topics: Clinical Trials as Topic; Double-Blind Method; Female; Fluphenazine; Humans; Male; Pimozide; Schizop | 1983 |
The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment.
Topics: Clinical Trials as Topic; Female; Fluphenazine; Follow-Up Studies; Humans; Male; Patient Readmission | 1983 |
Use of the Social Behaviour Assessment Schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic outpatients: pimozide versus fluphenazine.
Topics: Adult; Clinical Trials as Topic; Female; Fluphenazine; Humans; Male; Middle Aged; Outpatients; Pimoz | 1983 |
Depot fluphenazine: risk/benefit ratio.
Topics: Administration, Oral; Basal Ganglia Diseases; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Fe | 1984 |
The use of depot neuroleptics: clinical experience in the United States.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Depressive Disorder; Drug Administration Sche | 1984 |
A double-blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
Topics: Clinical Trials as Topic; Double-Blind Method; Female; Fluphenazine; Haloperidol; Humans; Male; Schi | 1984 |
Costs and benefits of two doses of fluphenazine.
Topics: Adult; Clinical Trials as Topic; Cost-Benefit Analysis; Double-Blind Method; Drug Administration Sch | 1984 |
Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
Topics: Adult; Depressive Disorder; Double-Blind Method; Female; Flupenthixol; Fluphenazine; Humans; Male; P | 1983 |
A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia.
Topics: Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Fluphenazine; Haloperidol; Human | 1995 |
Pharmacotherapy of impaired affect in recovering schizophrenic patients.
Topics: Adolescent; Adult; Ambulatory Care; Antipsychotic Agents; Anxiety Disorders; Basal Ganglia Diseases; | 1995 |
Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial.
Topics: Adult; Antipsychotic Agents; Benztropine; Delayed-Action Preparations; Depressive Disorder; Double-B | 1994 |
A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
Topics: Adult; Ambulatory Care; Basal Ganglia Diseases; Chronic Disease; Delayed-Action Preparations; Double | 1994 |
Fluphenazine treatment of DSM-III-R male schizophrenic patients among the Xhosa.
Topics: Adolescent; Adult; Ethnicity; Fluphenazine; Humans; Length of Stay; Male; Middle Aged; Psychiatric S | 1994 |
Stabilization and depot neuroleptic dosages.
Topics: Adult; Delayed-Action Preparations; Fluphenazine; Humans; Male; Schizophrenia | 1993 |
Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study.
Topics: Acute Disease; Adult; Clinical Trials as Topic; Combined Modality Therapy; Data Interpretation, Stat | 1996 |
Paracetamol self-poisoning. Characteristics, prevention and harm reduction.
Topics: Acetaminophen; Adolescent; Adult; Chemical and Drug Induced Liver Injury; Delayed-Action Preparation | 1996 |
Substance use: a powerful predictor of relapse in schizophrenia.
Topics: Adult; Antipsychotic Agents; Comorbidity; Diagnosis, Dual (Psychiatry); Dose-Response Relationship, | 1996 |
Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia.
Topics: Adult; Age of Onset; Ambulatory Care; Behavior Therapy; Combined Modality Therapy; Fluphenazine; Hum | 1996 |
Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment.
Topics: Adolescent; Adult; Ambulatory Care; Combined Modality Therapy; Delayed-Action Preparations; Dose-Res | 1997 |
Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
Topics: Adult; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Fluph | 1997 |
Generic substitution--comparing the clinical efficacy of a generic substitute for fluphenazine decanoate with the original product.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Double-Blind Method; Dru | 1998 |
P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Anxiety; Attention; Cognition; Depression; Evoked | 1998 |
Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks.
Topics: Adult; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Fluph | 1999 |
Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients.
Topics: Ambulatory Care; Brief Psychiatric Rating Scale; Drug Therapy, Combination; Fluphenazine; Humans; Li | 1999 |
Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Cross-Over Studies; Double-Blind Method; Fluphenazine; Foll | 2001 |
Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate.
Topics: Adult; Dose-Response Relationship, Drug; Drug Monitoring; Female; Fluphenazine; Humans; Male; Middle | 2002 |
Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress.
Topics: Adolescent; Adult; Attitude to Health; Autonomic Nervous System; Double-Blind Method; Female; Fluphe | 1992 |
Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress.
Topics: Adolescent; Adult; Attitude to Health; Autonomic Nervous System; Double-Blind Method; Female; Fluphe | 1992 |
Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress.
Topics: Adolescent; Adult; Attitude to Health; Autonomic Nervous System; Double-Blind Method; Female; Fluphe | 1992 |
Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress.
Topics: Adolescent; Adult; Attitude to Health; Autonomic Nervous System; Double-Blind Method; Female; Fluphe | 1992 |
The determination of the steady-state pharmacokinetic profile of fluphenazine decanoate by gas chromatography/mass spectrometry detection.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flup | 1992 |
Psychiatrists and citizens.
Topics: Chronic Disease; Double-Blind Method; Ethics, Medical; Fluphenazine; Humans; Informed Consent; Schiz | 1991 |
Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
Topics: Adult; Akathisia, Drug-Induced; Delayed-Action Preparations; Dose-Response Relationship, Drug; Doubl | 1991 |
[Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia].
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Fluphenazine; Haloperidol; Humans; Remission Induction; | 1990 |
Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
Topics: Adult; Aged; Biological Availability; Double-Blind Method; Female; Fluphenazine; Half-Life; Haloperi | 1990 |
A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Clinical Trials as Topic; Delayed-Ac | 1989 |
Neuroleptic dose reduction in persistently psychotic patients.
Topics: Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Fluph | 1989 |
A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Female; Fluphenazine; Hu | 1989 |
Imipramine-responsive panic-like symptomatology in schizophrenia/schizoaffective disorder.
Topics: Adult; Benztropine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Fear; | 1989 |
An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
Topics: Clinical Trials as Topic; Female; Flupenthixol; Fluphenazine; Humans; Male; Middle Aged; Psychiatric | 1989 |
The dysphoric syndrome in schizophrenia and its implications for relapse.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Female; Fluphenazine; Fol | 1989 |
Tardive dystonia. The benefits of time.
Topics: Adult; Chlorpromazine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Dys | 1989 |
[Oxyprothepin decanoate in maintenance therapy of schizophrenia--a double-blind, standardized controlled study].
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Dibenzothiepins; Double-Blind Method; Female; | 1985 |
Low-dose treatment strategies.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, | 1986 |
Comparative study of four evaluation criteria in a clinical trial with schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Fluphenazine; Humans; Middle Aged; Nursing; P | 1986 |
Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities.
Topics: Adult; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluphenazine; Humans; Male; Middl | 1988 |
Postpsychotic depression and negative symptoms: an investigation of syndromal overlap.
Topics: Adolescent; Adult; Aged; Benztropine; Clinical Trials as Topic; Depressive Disorder; Double-Blind Me | 1988 |
Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Fluphenazine; Humans; Kinetics; Male; Middle A | 1986 |
Antidepressants in the treatment of post-psychotic depression in schizophrenia: drug interactions and other considerations.
Topics: Adult; Affective Disorders, Psychotic; Benztropine; Clinical Trials as Topic; Drug Interactions; Flu | 1988 |
Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Fluphenazine; H | 1987 |
Persistence of fluphenazine in plasma after decanoate withdrawal.
Topics: Adult; Female; Fluphenazine; Humans; Male; Radioimmunoassay; Schizophrenia; Substance Withdrawal Syn | 1988 |
Family attitudes and patient social adjustment in a longitudinal study of outpatient schizophrenics receiving low-dose neuroleptics: the family's view.
Topics: Adolescent; Adult; Attitude; Dose-Response Relationship, Drug; Family; Female; Fluphenazine; Humans; | 1988 |
Bioavailability of psychotropic drugs: historical perspective and pharmacokinetic overview.
Topics: Biological Availability; Clinical Trials as Topic; Drug Evaluation; Fluphenazine; Humans; Kinetics; | 1986 |
Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
Topics: Adult; Body Weight; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Fema | 1986 |
A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; | 1986 |
Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Drug Therapy, Combination | 1987 |
Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome.
Topics: Adult; Akathisia, Drug-Induced; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Indu | 1987 |
Targeted treatment of depression-like symptoms in schizophrenia.
Topics: Benztropine; Depression; Drug Therapy, Combination; Fluphenazine; Humans; Imipramine; Schizophrenia | 1987 |
[Social integration of long-term paraphrenic patients with low-dose depot neuroleptic medication].
Topics: Adult; Aged; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Fluphenazine; Human | 1985 |
Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial I. Course of illness, stability of diagnosis, and the role of a special maintenance clinic.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; | 1985 |
Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression.
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Depressive Disorder; Double-Blind Method; Dys | 1985 |
Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome.
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Fluphenazine; Follow-Up Studies; Humans; Recu | 1985 |
Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients.
Topics: Adult; Female; Fluphenazine; Humans; Male; Middle Aged; Prolactin; Schizophrenia | 1985 |
Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
Topics: Adult; Double-Blind Method; Female; Fluphenazine; Haloperidol; Humans; Male; Middle Aged; Schizophre | 1985 |
121 other studies available for fluphenazine depot and Schizophrenia
| Article | Year |
|---|---|
Fluphenazine decanoate-induced bradycardia: A case report.
Topics: Adult; Antipsychotic Agents; Bradycardia; Delayed-Action Preparations; Fluphenazine; Humans; Male; S | 2022 |
Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Fluphenazine; Haloperidol; Human | 2013 |
Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Fluphenazine | 2013 |
Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Drug Combinations; Female; Fluphenazine; H | 2013 |
Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Sch | 2009 |
Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relati | 2010 |
The challenge of patients with severe psychiatric illness who do not access care - a way forward.
Topics: Antipsychotic Agents; Community Mental Health Services; Female; Fluphenazine; Health Behavior; Healt | 2010 |
[Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
Topics: Adult; Antipsychotic Agents; Cross-Sectional Studies; Delayed-Action Preparations; Dose-Response Rel | 2013 |
The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Delayed-Action Preparations; Dose | 2002 |
Rehospitalization risk with second-generation and depot antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Data Collection; Delayed-Action Preparation | 2003 |
Importance of oral glucose tolerance test in patient with schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Fluphenazine; Glucose Tolerance T | 2005 |
Who receives long-acting antipsychotic medications?
Topics: Antipsychotic Agents; Black People; Dangerous Behavior; Drug Utilization; Fluphenazine; Humans; Prej | 2007 |
Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia.
Topics: Administration, Oral; Adult; Alcoholism; Antipsychotic Agents; Black People; Cohort Studies; Comorbi | 2007 |
Switching as only temporal solution for patients with antipsychotic-associated diabetes: further observations.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Clozapine; Diabetes Mellitus, Type 2; D | 2007 |
Early hospital experience with fluphenazine decanoate.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Drug Administration Schedule; Female; Fluphenazine; Fo | 1974 |
Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
Topics: Administration, Oral; Adult; Age Factors; Ambulatory Care; Antipsychotic Agents; Clozapine; Cross-Se | 2008 |
Prolonged dopamine receptor blockade in rats after termination of long-term depot fluphenazine.
Topics: Animals; Delayed-Action Preparations; Fluphenazine; Humans; Male; Rats; Receptors, Dopamine; Schizop | 1981 |
Neuroendocrine tests during treatment with neuroleptic drugs. II. The TRH test.
Topics: Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Female; Flupenthixol; Fluphenazine; | 1981 |
[Comparison between the effectiveness of fluphenazine decanoate and oxyprothepin decanoate in schizophrenia (double-blind crossover study)].
Topics: Adult; Antipsychotic Agents; Dibenzothiepins; Double-Blind Method; Female; Fluphenazine; Humans; Mal | 1982 |
Aftercare of schizophrenic patients: pharmacotherapy and consistency of therapists.
Topics: Administration, Oral; Adolescent; Adult; Aftercare; Antipsychotic Agents; Fluphenazine; Follow-Up St | 1983 |
The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Drug Administration Schedule; Female; Flupenthixol; Fl | 1983 |
Pharmacotherapy and suicide risk in schizophrenia.
Topics: Adult; Antipsychotic Agents; Depressive Disorder; Drug Therapy, Combination; Female; Fluphenazine; H | 1983 |
AMDP psychopathology factors in chronic schizophrenia: a clinical trial of two long-acting neuroleptics.
Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Female; Fluphenazine; Humans; Male; Middle | 1983 |
[What should we recommend for schizophrenic patients: long-term drug prevention or interval treatment?].
Topics: Ambulatory Care; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Administration Sch | 1983 |
Abnormal involuntary movements in patients on long-acting neuroleptics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cross-Sectional Studies; Dose-Response Relationship, | 1983 |
The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
Topics: Administration, Oral; Antipsychotic Agents; Basal Ganglia Diseases; Biological Availability; Chronic | 1984 |
Standard v optimal dose.
Topics: Ambulatory Care; Antipsychotic Agents; Drug Administration Schedule; Fluphenazine; Humans; Schizophr | 1984 |
Information processing and neuroleptic response in acute and stabilized schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Cognition; Fluphenazine; Haloperidol; Humans; Male; Pattern Recognition | 1984 |
[Follow-up study of patients treated with depot phenothiazines in Valparaiso, Chile].
Topics: Adolescent; Adult; Aged; Chile; Female; Fluphenazine; Follow-Up Studies; Humans; Male; Mental Disord | 1981 |
[Clinical experience with depot neuroleptic treatment].
Topics: Female; Fluphenazine; Hallucinations; Humans; Male; Prognosis; Psychotic Disorders; Schizophrenia; S | 1984 |
Intervals between long acting neuroleptics: outcome and re-admission variables.
Topics: Age Factors; Chronic Disease; Female; Fluphenazine; Follow-Up Studies; Humans; Male; Patient Readmis | 1984 |
Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine.
Topics: Adult; Basal Ganglia Diseases; Bromocriptine; Dantrolene; Drug Therapy, Combination; Fluphenazine; H | 1983 |
[Clinical significance of depot fluphenazine decanoate in therapy of acute psychotic disorders].
Topics: Acute Disease; Adolescent; Adult; Aged; Bipolar Disorder; Delayed-Action Preparations; Female; Fluph | 1983 |
Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives.
Topics: Adolescent; Adult; Double-Blind Method; Drug Therapy, Combination; Fluphenazine; Humans; Lithium; Mi | 1984 |
Fluphenazine and tardive dyskinesia.
Topics: Delayed-Action Preparations; Drug Administration Schedule; Dyskinesia, Drug-Induced; Fluphenazine; H | 1984 |
Suicide associated with akathisia and depot fluphenazine treatment.
Topics: Adult; Akathisia, Drug-Induced; Dyskinesia, Drug-Induced; Fluphenazine; Humans; Male; Psychomotor Ag | 1983 |
Experience with fluphenazine decanoate in the management of chronic schizophrenic outpatients.
Topics: Adult; Ambulatory Care; Delayed-Action Preparations; Female; Fluphenazine; Follow-Up Studies; Humans | 1982 |
Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate.
Topics: Adult; Delayed-Action Preparations; Depression; Drug Interactions; Drug Therapy, Combination; Female | 1982 |
[Treatment of schizophrenic psychoses by sustained-action neuroleptics in psychiatric outpatients' treatment (author's transl)].
Topics: Adult; Aged; Ambulatory Care; Delayed-Action Preparations; Female; Fluphenazine; Humans; Male; Middl | 1982 |
Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
Topics: Chronic Disease; Delayed-Action Preparations; Double-Blind Method; Fluphenazine; Humans; Psychiatric | 1982 |
Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
Topics: Adult; Aged; Chronic Disease; Double-Blind Method; Dyskinesia, Drug-Induced; Fluphenazine; Humans; M | 1982 |
Fluphenazine blood levels and clinical response.
Topics: Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Fluphenazine; Humans; Radiol | 1982 |
A double-blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia.
Topics: Adult; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Fluphenazine; Fluspirilene; Humans; Ma | 1982 |
[Modification of schizophrenia by intensive neuroleptic therapy and the course of the disease after withdrawal of neuroleptic drugs].
Topics: Adolescent; Adult; Aged; Child; Drug Administration Schedule; Fluphenazine; Follow-Up Studies; Human | 1980 |
[Group psychotherapy of chronic schizophrenics in an external milieu].
Topics: Adult; Ambulatory Care; Chronic Disease; Female; Fluphenazine; Humans; Male; Middle Aged; Psychoanal | 1981 |
Follow-up study of 281 schizophrenic patients treated with high dosage fluphenazine decanoate.
Topics: Age Factors; Dyskinesia, Drug-Induced; Female; Fluphenazine; Follow-Up Studies; Humans; Recurrence; | 1981 |
The use of fluphenazine decanoate (Modecate)depot therapy in outpatient schizophrenics-a retrospective study.
Topics: Adolescent; Adult; Ambulatory Care; Child; Delayed-Action Preparations; Female; Fluphenazine; Humans | 1981 |
[Clinical observation on the effect of domestic fluphenazine decanoate in the treatment of schizophrenia---report of 431 cases (author's transl)].
Topics: Adolescent; Adult; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Fluphenazi | 1981 |
Schizophrenic patients' perceptions of their relatives' attitudes.
Topics: Adult; Affect; Antipsychotic Agents; Black or African American; Family; Fluphenazine; Humans; Middle | 1995 |
Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate.
Topics: Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Dr | 1995 |
Death due to benzhexol toxicity.
Topics: Bronchopneumonia; Cause of Death; Death, Sudden; Dyskinesia, Drug-Induced; Empyema, Pleural; Fatal O | 1995 |
Factors affecting rehospitalisation rates of chronic schizophrenic patients living in the community.
Topics: Adult; Aged; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Sche | 1994 |
Cocaine use by schizophrenic outpatients who receive depot neuroleptic medication.
Topics: Adult; Ambulatory Care; Chronic Disease; Cocaine; Combined Modality Therapy; Comorbidity; Delayed-Ac | 1993 |
Diphenhydramine dependence: a need for awareness.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Diphenhydramine; Fluphenazine; Humans; Mal | 1996 |
Two-year trial of maintenance neuroleptic dose reduction in schizophrenic out-patients: predictors of relapse.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Fluphenazine | 1995 |
Intervention and social breakdown in the elderly.
Topics: Aged; Combined Modality Therapy; Community Mental Health Services; Ethics, Medical; Female; Fluphena | 1996 |
Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Fluphenazine; Humans; Male; Muscarinic Ant | 1996 |
Absence of parkinsonism among patients in long-term neuroleptic therapy who abuse cocaine.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cocaine; Comorbidity; Delayed-Action Preparations; Flu | 1997 |
Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone.
Topics: Antipsychotic Agents; Baltimore; Chronic Disease; Delayed-Action Preparations; Disease-Free Survival | 1998 |
Alcohol dependence and hospitalization in schizophrenia.
Topics: Adult; Alcoholism; Antipsychotic Agents; Cocaine-Related Disorders; Comorbidity; Female; Fluphenazin | 1999 |
Age at onset of schizophrenia and neuroleptic dosage.
Topics: Adult; Age of Onset; Antipsychotic Agents; Clopenthixol; Dose-Response Relationship, Drug; Female; F | 1999 |
Increased incidence of dyskinesias and other behavioral effects of re-exposure to neuroleptic treatment in social colonies of Cebus apella monkeys.
Topics: Aggression; Animals; Antipsychotic Agents; Cebus; Dyskinesia, Drug-Induced; Female; Fluphenazine; Lo | 2001 |
Lowest effective dose of depot neuroleptics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationsh | 1992 |
Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation.
Topics: Administration, Oral; Antipsychotic Agents; Chronic Disease; Drug Therapy, Combination; Dyskinesia, | 1992 |
Predictors of the course of tardive dyskinesia in patients receiving neuroleptics.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; F | 1992 |
Psychotic symptoms preceding ocular deviation in a patient with tardive oculogyric crises.
Topics: Adult; Antipsychotic Agents; Benztropine; Chlorpromazine; Dose-Response Relationship, Drug; Dyskines | 1992 |
Life events and schizophrenic relapse after withdrawal of medication.
Topics: Adaptation, Psychological; Adult; Female; Fluphenazine; Humans; Injections, Intramuscular; Life Chan | 1992 |
Facial dyskinesia: a 16-year follow-up study.
Topics: Affective Disorders, Psychotic; Aged; Antipsychotic Agents; Brain; Chlorpromazine; Dose-Response Rel | 1991 |
Tardive oculogyric crisis and obsessional thoughts.
Topics: Dyskinesia, Drug-Induced; Female; Fluphenazine; Humans; Middle Aged; Obsessive-Compulsive Disorder; | 1991 |
Alcohol abuse in chronic schizophrenics: implications for management in the community.
Topics: Adult; Alcohol Drinking; Alcoholism; Chronic Disease; Community Mental Health Services; Delayed-Acti | 1991 |
[Clinico-economical aspects of long-term therapy with moditen-depot].
Topics: Cost-Benefit Analysis; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Tolerance | 1990 |
An unusual presentation of neuroleptic malignant syndrome.
Topics: Adult; Dose-Response Relationship, Drug; Fluphenazine; Humans; Male; Neuroleptic Malignant Syndrome; | 1991 |
Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
Topics: Aged; Basal Ganglia Diseases; Blood Pressure; Electrocardiography; Electroencephalography; Female; F | 1990 |
Noninvasive in vivo detection of a fluorinated neuroleptic in the human brain by 19F nuclear magnetic resonance spectroscopy.
Topics: Adult; Brain Chemistry; Fluorine; Fluphenazine; Humans; Magnetic Resonance Spectroscopy; Male; Schiz | 1990 |
Symptomatic trans-sexualism.
Topics: Adult; Delayed-Action Preparations; Delusions; Fluphenazine; Humans; Schizophrenia; Schizophrenic Ps | 1990 |
Use of extremely low doses of fluphenazine decanoate.
Topics: Ambulatory Care; Delayed-Action Preparations; Female; Fluphenazine; Humans; Mental Disorders; Middle | 1990 |
Patients' and caregivers' adaptation to improvement in schizophrenia.
Topics: Adult; Assertiveness; Depressive Disorder; Drug Therapy, Combination; Family; Female; Fluphenazine; | 1990 |
Return of sense of taste with fluphenazine.
Topics: Brain; Dose-Response Relationship, Drug; Fluphenazine; Humans; Injections, Intramuscular; Neurocogni | 1989 |
Fluphenazine decanoate: a clinical problem?
Topics: Antipsychotic Agents; Chlorpromazine; Dose-Response Relationship, Drug; Fluphenazine; Haloperidol; H | 1989 |
Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; F | 1989 |
Prescribing patterns of neuroactive drugs in 98 schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Drug Therapy, Combination; Female; Fluphenazine; Humans; Ma | 1989 |
Tardive dyskinesia in outpatients on depot phenothiazine.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antipsychotic Agents; Delayed-Action Preparations; | 1989 |
Trials of adjunctive alprazolam in "negative symptom" patients.
Topics: Adult; Alprazolam; Depressive Disorder; Drug Therapy, Combination; Fluphenazine; Hallucinations; Hum | 1989 |
Compliance in the long-term treatment of schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Fluphenazine; Humans; Patient Compliance; Recurrence; Sc | 1985 |
[Intensive psychopharmacologic therapy of slowly-progressive schizophrenia].
Topics: Adult; Antipsychotic Agents; Chlordiazepoxide; Diazepam; Female; Fluphenazine; Humans; Infusions, Pa | 1985 |
Selection of neuroleptic dosage.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluphenazine; | 1985 |
Tardive dyskinesia and current dose of neuroleptic drugs.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Flupenthixo | 1985 |
Heatstroke in a chronic schizophrenic patient treated with high-potency neuroleptics.
Topics: Antipsychotic Agents; Benztropine; Chronic Disease; Dose-Response Relationship, Drug; Drug Therapy, | 1985 |
Tardive dyskinesia in schizophrenics under 60 years of age.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Dyskinesia, Drug-Ind | 1986 |
[Clinical picture, therapy and rehabilitation of patients with slowly-progressive (psychopath-like) schizophrenia with a loss of work capacity].
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Central Ne | 1986 |
[Considerations on the use of long-acting neuroleptics in a mental health center].
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Delayed-Action Preparations; Depression; Fluphenazine; | 1986 |
[Substitution of fluphenazine decanoate with oxyprothepine decanoate in long-term maintenance therapy in schizophrenia].
Topics: Dibenzothiepins; Female; Fluphenazine; Humans; Male; Schizophrenia | 1986 |
Neuroleptic effects on platelet aggregation: a study in normal volunteers and schizophrenics.
Topics: Adolescent; Adult; Antipsychotic Agents; Chlorpromazine; Delayed-Action Preparations; Flupenthixol; | 1987 |
Clinical symptomatology and drug compliance in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Flupenthixol; Fluphenazine; Fluspi | 1988 |
Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate.
Topics: Adult; Antipsychotic Agents; Clopenthixol; Female; Fluphenazine; Humans; Male; Middle Aged; Schizoph | 1988 |
Effects of neuroleptic treatments on peripheral opioid secretion.
Topics: Adult; Antipsychotic Agents; beta-Endorphin; beta-Lipotropin; Chlorpromazine; Chronic Disease; Diben | 1987 |
Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view.
Topics: Adult; Antipsychotic Agents; Female; Fluphenazine; Follow-Up Studies; Humans; Male; Middle Aged; Pat | 1988 |
Fluphenazine decanoate in acute and maintenance therapy of schizophrenia.
Topics: Acute Disease; Adult; Female; Fluphenazine; Humans; Long-Term Care; Male; Middle Aged; Psychiatric S | 1987 |
The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate.
Topics: Fluphenazine; Gas Chromatography-Mass Spectrometry; Humans; Male; Radioimmunoassay; Schizophrenia | 1987 |
[Results of long-term treatment with depot neuroleptics in schizophrenic patients].
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Fluphenazine; Humans; Long-Term Care | 1988 |
Plasma levels of fluphenazine and prolactin in psychiatric patients.
Topics: Adult; Female; Fluphenazine; Humans; Male; Middle Aged; Personality Disorders; Prolactin; Schizophre | 1988 |
Continuation and maintenance treatment trials of adjunctive imipramine therapy in patients with postpsychotic depression.
Topics: Benztropine; Depressive Disorder; Drug Therapy, Combination; Fluphenazine; Humans; Imipramine; Psych | 1988 |
Plasma levels of fluphenazine decanoate. Effects of site of injection, massage and muscle activity.
Topics: Adolescent; Adult; Chronic Disease; Delayed-Action Preparations; Fluphenazine; Humans; Injections, I | 1988 |
Patterns of plasma imipramine-desipramine concentrations in patients receiving concomitant fluphenazine decanoate.
Topics: Adult; Depressive Disorder; Desipramine; Dose-Response Relationship, Drug; Drug Interactions; Drug T | 1988 |
Changing from oral to depot fluphenazine.
Topics: Administration, Oral; Body Weight; Drug Administration Schedule; Fluphenazine; Humans; Schizophrenia | 1988 |
Depot neuroleptic medication and serum levels by radioreceptor assay: prolactin concentration, electrocardiogram abnormalities and six-month outcome.
Topics: Adult; Delayed-Action Preparations; Dose-Response Relationship, Drug; Electrocardiography; Female; F | 1987 |
L-5-Hydroxytryptophan-induced delirium.
Topics: 5-Hydroxytryptophan; Administration, Oral; Adult; Delirium; Double-Blind Method; Drug Therapy, Combi | 1986 |
Family psychoeducation, social skills training, and medication in schizophrenia: the long and short of it.
Topics: Behavior Therapy; Combined Modality Therapy; Family Therapy; Fluphenazine; Humans; Schizophrenia | 1987 |
Invitation to compliance. The Prolixin brunch.
Topics: Adult; Delayed-Action Preparations; Female; Fluphenazine; Humans; Male; Middle Aged; Patient Complia | 1987 |
Plasma prolactin and fluphenazine concentrations in patients receiving fluphenazine decanoate: stability over injection intervals.
Topics: Adult; Female; Fluphenazine; Humans; Male; Middle Aged; Prolactin; Schizophrenia | 1987 |
Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Chronic Disease; Female; Fluphenazine; Humans; Injections, | 1986 |
Is postpsychotic depression a primary affective disorder?
Topics: Depressive Disorder; Fluphenazine; Humans; Psychotic Disorders; Schizophrenia | 1986 |
Expressed emotion, fixed-dose fluphenazine decanoate maintenance, and relapse in recent-onset schizophrenia.
Topics: Adult; Emotions; Family; Female; Fluphenazine; Humans; Male; Recurrence; Schizophrenia; Schizophreni | 1986 |
Flupenthixol decanoate and fluphenazine decanoate in chronic schizophrenia.
Topics: Adult; Chronic Disease; Female; Flupenthixol; Fluphenazine; Humans; Male; Middle Aged; Schizophrenia | 1985 |
Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia.
Topics: Adolescent; Adult; Chromatography, Gas; Female; Fluphenazine; Humans; Male; Schizophrenia | 1985 |
[Depressive syndromes within the scope of schizophrenic psychoses].
Topics: Depressive Disorder; Fluphenazine; Hallucinations; Humans; Long-Term Care; Male; Models, Psychologic | 1985 |
Stability of the postpsychotic depression syndrome.
Topics: Adult; Depressive Disorder; Female; Fluphenazine; Humans; Male; Middle Aged; Outcome and Process Ass | 1986 |
Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
Topics: Adult; Aged; Chronic Disease; Dose-Response Relationship, Drug; Female; Fluphenazine; Humans; Male; | 1985 |
Long-acting therapy of schizophrenia.
Topics: Adolescent; Adult; Antiparkinson Agents; Benzodiazepines; Biofeedback, Psychology; Bromocriptine; Dy | 1985 |
Plasma levels of neuroleptic in patients receiving depot fluphenazine.
Topics: Delayed-Action Preparations; Fluphenazine; Humans; Regression Analysis; Schizophrenia | 1985 |
Depot fluphenazine and plasma prolactin.
Topics: Drug Tolerance; Female; Fluphenazine; Humans; Male; Prolactin; Schizophrenia; Sex Factors | 1985 |